SEC Comment Letter 0000000000-24-001266 to Rein Therapeutics, Inc. (RNTX)
Rein Therapeutics, Inc.
Date: Feb. 1, 2024 · CIK: 0001420565 · Accession: 0000000000-24-001266
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-276746
Letter
United States securities and exchange commission logo February 1, 2024 Manuel Alves-Aivado Chief Executive Officer Aileron Therapeutics Inc. 738 Main Street #398 Waltham, MA 02451 Re:Aileron Therapeutics Inc. Registration Statement on Form S-3 Filed January 29, 2024 File No. 333-276746 Dear Manuel Alves-Aivado: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Craig Hilts
Show Raw Text
United States securities and exchange commission logo
February 1, 2024
Manuel Alves-Aivado
Chief Executive Officer
Aileron Therapeutics Inc.
738 Main Street #398
Waltham, MA 02451
Re:Aileron Therapeutics Inc.
Registration Statement on Form S-3
Filed January 29, 2024
File No. 333-276746
Dear Manuel Alves-Aivado:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Craig Hilts